Lone Risperdal Defense Verdict for J&J Overturned
The Chamber: ‘One More Bullet in J&J’s Gun’
In ‘For Plaintiffs Bar, Taking on J&J Means Battling a Shadow Foe,’ Law.com’s Amanda Bronstad reports on the “intimate relationship” between Johnson & Johnson (J&J) and the U.S. Chamber of Commerce (the Chamber). The U.S. Chamber of Commerce is not a government entity, but a powerful group of lobbyists, the largest in the nation. Plaintiff’s lawyers point out […]
High Court Won’t Hear Sheller Dispute with FDA over Risperdal
High Court Won’t Hear Dispute Challenging FDA Over J&J Drug Supreme Court won’t weigh in on whether law firm can sue FDA over drug labeling Circumstances in which third parties can sue over government actions remain unclear By Dana A. Elfin A Philadelphia-based law firm has hit the end of the road in its bid […]
Risperdal News: Sheller Quoted in Toronto Star
Stephen Sheller was quoted in a July 31, 2015 article discussing Risperdal research that was “manipulated by a drug company and understated the risks of a powerful antipsychotic used to treat kids with behavioural problems.” In the news story, pediatrician Denis Daneman says there was no intent on his part to exclude “significant results” from […]
Sheller Spars With FDA
Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as […]
In The New York Times: “Side Effects May Include Lawsuits”
One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]
